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Background: Vancomycin-resistant isolates of E. faecalis and E. faecium are of special concern and patients at risk of
acquiring a VRE colonization/infection include also intensively-cared neonates. We describe here an ongoing high
prevalence of VanB type E. faecium in a neonatal ICU hardly to identify by routine diagnostics.
Methods: During a 10 months’ key period 71 E. faecium isolates including 67 vanB-type isolates from 61 patients
were collected non-selectively. Vancomycin resistance was determined by different MIC methods (broth
microdilution, VitekW 2) including two EtestW protocols (McFarland 0.5/2.0. on Mueller-Hinton/Brain Heart Infusion
agars). Performance of three chromogenic VRE agars to identify the vanB type outbreak VRE was evaluated
(BrillianceTM VRE agar, chromIDTM VRE agar, CHROMagarTM VRE). Isolates were genotyped by SmaI- and CeuI-
macrorestriction analysis in PFGE, plasmid profiling, vanB Southern hybridisations as well as MLST typing.
Results: Majority of vanB isolates (n = 56, 79%) belonged to a single ST192 outbreak strain type showing an
identical PFGE pattern and analyzed representative isolates revealed a chromosomal localization of a vanB2-Tn5382
cluster type. Vancomycin MICs in cation-adjusted MH broth revealed a susceptible value of ≤4 mg/L for 31 (55%) of
the 56 outbreak VRE isolates. EtestW vancomycin on MH and BHI agars revealed only two vanB VRE isolates with a
susceptible result; in general EtestW MIC results were about 1 to 2 doubling dilutions higher than MICs assessed in
broth and values after the 48 h readout were 0.5 to 1 doubling dilutions higher for vanB VRE. Of all vanB type VRE
only three, three and two isolates did not grow on BrillianceTM VRE agar, chromIDTM VRE agar and CHROMagarTM
VRE, respectively. Permanent cross contamination via the patients’ surrounding appeared as a possible risk factor for
permanent VRE colonization/infection.
Conclusions: Low level expression of vanB resistance may complicate a proper routine diagnostics of vanB VRE and
mask an ongoing high VRE prevalence. A high inoculum and growth on rich solid media showed the highest
sensitivity in identifying vanB type resistance.* Correspondence: wernerg@rki.de
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A recent Health Care report of the European Center for
Disease Prevention and Control lists Enterococcus spp. as
the second most prevalent ICU-acquired bloodstream and
urinary tract infection pathogen [1]. Special problems are
linked to multi- and vancomycin-resistant variants hardly
to treat by standard antibiotic regimes. The reservoir
of acquired vancomycin resistance is in the species
E. faecium. Altogether eight types of acquired vanco-
mycin resistance genotypes vanA-vanN are known in en-
terococci with vanA the worldwide most prevalent
genotype followed by vanB [2]. VanB type resistance is
characterized by resistance to vancomycin and susceptibil-
ity to other glycopeptides like teicoplanin since only the
former antibiotic is capable of inducing the vanB resistance
type. Levels of expression of vancomycin resistance are
generally higher in VanA than in VanB type strains mean-
ing MICs against vancomycin are several dilution steps
higher in VanA (commonly 16–512 mg/L) than in VanB
strains (4–64 mg/L). Low level vancomycin resistance ex-
pression especially in VanB strains may complicate per-
formance of diagnostic assays assessing the resistance
phenotype and predicting the corresponding genotype.
During recent years, clusters of infections and coloniza-
tions with vanB genotype E. faecium increased in a number
of European countries. Sweden experienced several out-
breaks with vanB type VRE [3] and country-wide surveil-
lance of VRE notified an increasing number of vanB-type
VRE in low prevalence countries like France [4]. The PCR-
determined vanB type ligase gene appears in three allelic
variants with vanB2 as the most frequent. The vanB2 gene
is part of similar “Integrative and Conjugative Elements”
(ICE) of the Tn5382- and Tn1549-types and thus transfer-
able as well [5]. Common vanB type clusters were most
often chromosomally located as, for instance, described for
the E. faecalis type strain V583 [6]. The recent outbreaks
of VanB strains in Sweden were linked to vanB2-Tn5382
elements located on transferable pRUM-like plasmids [7,8].
In Germany, different surveillance schemes exist in paral-
lel assessing also numbers of clinical cases and VRE/entero-
coccal infections in general. Despite having different
denominators and foci, they mainly report similar frequen-
cies of vancomycin resistance among E. faecium from colo-
nizations and infections in hospital patients being around
10–15% in recent years [9,10]. The vanA genotype was the
most wide-spread for many years in Germany and clusters
of infections with vanB type VRE remained exceptional;
however, this has changed since 2008 [10]. In a background
of similar levels of vancomycin resistance, data of a number
of surveillance schemes showed a permanent decrease in
frequency of teicoplanin resistance since 2008, a marker of
VanB type resistance. This has been confirmed by a geno-
typic assessment of resistance genotypes and is represented
in the growing number of VanB strains sent to the GermanFocal laboratory for enterococci; from 2009 to 2011 more
vanB type VRE than vanA type VRE were received repre-
senting outbreaks or an ongoing high overall prevalence of
infections and colonisations with vanB type E. faecium in
more than 20 university hospitals countrywide (Klare et al.,
unpublished data). Here we report a molecular-
epidemiological investigation of a cluster of vanB type VRE
cases in neonatal patients of a single ICU during an
10 months’ period. VRE were identified by a non-selective
stool sample screening and subsequent VRE identification/
confirmation. From this key period altogether 71 VRE were
subjected to a deeper molecular analysis.
Methods
Hospital setting
The neonatal ICU belongs to a hospital of tertiary care
(2.300 beds) located in South-Western Germany. It con-
sists actually of two units with one containing 16 beds in
four rooms and an additional one containing 20 beds in
5 rooms. Unit 1 offers the possibility of mechanical ven-
tilation; patients are regularly transferred between the
two units. The setting is conceptually a mixed ward
allowing also older, pediatric patients to be admitted into
two of the rooms. The neonatal ICU is a so-called “Peri-
neonatology level 1 Centre” with an annual number of
about 50 neonatal patients with a low birth weight of
<1.500 g.
Patient setting, bacterial isolates and primary diagnostics
During a period of September 2008 until June 2009
altogether 598 patients attending a neonatal ICU were
screened non-selectively for enterococci. Columbia Agar
with sheep blood (COL SB; Oxoid, Wesel, Germany)
was used to isolate enterococci from different clinical
samples. E. faecium was identified by using standard
microbiological methods including hydrolyzing esculin
and growth in 6.5% NaCl and by API 20 Strep
(bioMérieux, Nürtingen, Germany). Randomly chosen
enterococcal isolates were subsequently tested for resist-
ance to vancomycin by routine diagnostics using agar
diffusion or EtestW Vancomycin (bioMérieux). Suscepti-
bility interpretations followed the guidelines proposed by
CLSI (S ≤4; I =8/16; R ≥32 mg/L). Vancomycin resist-
ance genotypes (vanA, vanB or vanC) were determined
by a PCR and Southern hybridization based assay
(GenoTypeW Enterococcus, Hain Lifescience, Nehren,
Germany). Discrepancies between phenotypic (suscep-
tible) and genotypic (vanB-positive) results lead to the
general agreement to test all isolates for vanB with an in-
hibition zone of ≤18 mm around a vancomycin disk by a
genotypic method. Seventy-one pre-selected E. faecium
isolates were sent for vanB type confirmation and clonal
analysis to the German focal laboratory for enterococci at
the Robert Koch Institute.
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For all 71 E. faecium isolates antibiotic susceptibilities
were determined for 14 antibiotics as minimal inhibitory
concentrations (MIC) using a microdilution method in
cation-adjusted Mueller-Hinton broth according to
international standards. We used the EUCAST clinical
breakpoints when available; for other antibiotics we ap-
plied breakpoints derived from CLSI, DIN and based on
other criteria (e.g., for high level ciprofloxacin resistance
>16 mg/L [11]). MICs were classified as resistant (in
mg/L) as follows: penicillin/ampicillin >8, vancomycin
>4; teicoplanin >2, erythromycin >4, linezolid >4, tetra-
cycline >4, rifampicin >0.5, chloramphenicol >16, tigecy-
cline >0.5, daptomycin >4, gentamicin (high-level) >128,
streptomycin (high-level) >512, quinupristin/dalfopristin
>4. Etest for vancomycin was performed according to
the recommendation of the manufacturer (bioMérieux).
In brief, two different protocols were followed. First, a
standard screening method with Mueller-Hinton agar
and an inoculum equivalent to McFarland 0.5 and sec-
ond, Brain Heart Infusion agar and an inoculum equiva-
lent to McFarland 2.0 was used. The latter one is called
EtestW macromethod and is suggested for a confirmation
of a supposed vancomycin resistance phenotype. Values
are read after incubation at 35°C for 24 and 48 h as
recommended (EtestW application sheet for Entero-
coccus/VRE and vancomycin EAS009). E. faecalis
ATCC29212 and E. faecium ATCC19434 were used as
control strains. Performance of three commercially avail-
able, chromogenic VRE screening agars was evaluated;
Oxoid BrillianceTM agar VRE (Thermo Scientific Fisher,
Wesel, Germany); chromIDTM VRE (bioMérieux) and
CHROMagarTM VRE (Mast Diagnostika, Reinfeld,
Germany). Strains were streaked out on selective plates
and incubated as recommended by the manufacturers.
Growth as single colonies and with the equivalent colours
was rated as a positive result.
DNA isolation
Genomic DNA was prepared using a DNA extraction kit
(DNeasy Tissue Kit; Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. An initial cell wall
lysis step was added dissolving the cell pellet in TES buf-
fer [10 mM Tris, 0.5 mM ethylene diamine tetra-acetic
acid (EDTA), 10% sucrose (pH 8.0)] plus 10 mg/mL
lysozyme (Roche Applied Science, Mannheim, Germany)
followed by incubation at 37°C for 30 min. Plasmids
were extracted according to an alkaline lysis protocol
and subsequent phenol/chloroform-based purification as
described recently [12].
PCR
PCR was performed with a PCR master mix (Thermo
Fisher Scientific; St. Leon-Rot, Germany) according to themanufacturer’s instructions. Exactly 0.5 μL of isolated
genomic DNA (ca. 10 ng) and primers (200 nM each)
were added. Amplification of fragments representing
the esp, hylEfm and vanA/B genes was performed in a
multiplex PCR as described elsewhere [12]. Subtyping
of vanB ligases and cluster types was done as
described recently [13,14]. Primers vanB-L1: 5’-
GTTTGATGCAGAGGCAGACGACT and vanB-L2 5’-
ACAAGTTCCCCTGTATCCAAGTGG were used to
amplify a 5,959 bp product using the Expand Long
Template PCR system and conditions set by the
manufacturer (Roche Applied Science, Mannheim,
Germany). Long PCR products were subsequently
digested with BspH1 and DraI for 2 h at 37°C and
resolved in 0.8% agarose gels. Plasmid replicase genes
were amplified as described [15,16]. PCR for IS16 was
performed as described [17]. The following strains
and plasmids were used as positive control samples:
plasmid pRUM (IS16, rep17 family), plasmid pLG1
(hylEfm, repA-N family, new subtype), plasmid pIP816
(vanA; E. faecium BM4147), E. faecium U0317 (esp),
and E. faecalis V583 (vanB) and E. faecalis RE25
pRE25 (inc18 rep2 family). E. faecalis OG1RF served
as a negative control sample for all PCR assays.
Mating experiments
Altogether nine ST192 strains (UW7606, UW7609,
UW7611, UW7612, UW7813, UW7819, UW7835,
UW7842, UW7845) were used as donors in in vitro
filter-mating experiments. The rifampicin- and fusidic
acid-resistant E. faecium strain 64/3 was used as a re-
cipient. Transconjugants were selected on BHI agar sup-
plemented with rifampicin (30 mg/L), fusidic acid
(20 mg/L) and vancomycin with various concentrations
according to the MIC of the donor strain (2, 4, 8 mg/L).
The mating protocol was performed and mating rates
were calculated as described recently [18]. Plates were
incubated at 37°C up to 48 h. Supposed transconjugants
were grown on selective plates and analyzed phenotypic-
ally (antibiotic susceptibilities) and genotypically
(PCR-based marker genes and PFGE).
PFGE analyses
Genomic DNA for PFGE analysis was isolated and trea-
ted as described recently [18]. The agarose gel concen-
tration was 1%, the CHEF-DR III apparatus (Bio-Rad
Laboratories, Hercules, CA, USA) was used for PFGE.
SmaI-digested Staphylococcus aureus NCTC 8325 was
used as a molecular mass standard on all PFGE gels.
Genomic DNA of the E. faecium isolates was digested
with SmaI. The ramped pulsed times were as follows: 1
– 11 s for 15 h and 11 – 30 s for 14 h at 14°C. Digestion
of genomic DNA with I-Ceu-I linearises chromosomal
DNA by recognizing the six rDNA operons in E. faecium
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DNA was digested with I-Ceu-I for 16 h at 37°C. The
ramped pulsed times for I-Ceu-I gels were 5 – 30 s for
22 h at 14°C [12].
Southern hybridizations
Southern hybridization experiments were done as described
elsewhere using a PCR-generated digoxigenin-labelled vanB
probe (DIG High Prime; Roche Applied Science),
hybridization chemicals and equipment from commercial
kits and according to recommendations of the manufac-
turer (Roche Applied Science). Immunological detection
was done as recommended using a chemiluminescent
probe (CDP-StarTM, Roche Applied Science) and several
readouts were taken at 10, 30, 60 and 120 min in a chemi-
imager from Bio-Rad (Chemidoc XRS, Bio-Rad Labs.,
Hercules, US).
MLST and DNA sequencing
PCRs amplifying the seven loci used for MLST were
done according to the reference (http://efaecium.mlst.
net/). Sequencing reactions were performed according to
the manufacturer’s recommendations for cycle sequen-
cing of PCR products (Life Technologies/Applied Biosys-
tems, Germany). Sequence files were read, evaluated,
aligned and compared to the reference set of alleles
using sequencing software Lasergene 8.0 from DNA-
STAR (SeqMan 8.0; EditSeq 8.0), TraceEditPro v. 1.1.1
from Ridom (www.ridom.de), and via the official MLST
webpage (http://efaecium.mlst.net/).
Statistics
Statistical analyses were performed with software pack-
age EpiCompare 1.0 (Ridom).
Results
Primary diagnostics
During a period of September 2008 until June 2009 al-
most 600 patients attending a neonatal ICU were
screened non-selectively for enterococci and altogether
80 VRE carriers were primarily diagnosed. Seventy-one
isolates including 67 vanB-type VRE and 4 vancomycin-
susceptible E. faecium were available for a detailed mo-
lecular analysis. The 67 vanB isolates were from 61
patients, four vanB VRE were from patients’ surround-
ings (control monitor, incubator holding, incubator mat-
tress) and from one patient three vanB-type E. faecium
were sampled within 23 days. All but one patients were
between 0–11 months old (a single case was 6 years
old). The median age was less than one month; the ma-
jority of babies had been transferred into the neonatal
ICU directly after birth where they were intensively
cared.Infection control measures
Since bundle measures are known to be effective espe-
cially in containing outbreaks with VRE [19] various in-
tensified infection prevention measures including an
intensified disinfection procedure were established soon
after the first cluster of VRE cases was identified. The
catalogue of all these measures should only be men-
tioned here in brief: (a) intensified screening for VRE to
define the extent of the scenario; (b) environmental sam-
pling to identify contaminated surfaces as possible
spreading sources; (c) introduction of barrier precau-
tions for medical personal (gowns, gloves, masks, etc.);
(d) permanent infection prevention and control training
focussing on preventing environmental contamination
and spread of pathogens; (e) interdisciplinary results’
discussion with medical staff and doctors; (f ) repeated
updating of an adequate antibiotic therapy; (g) rectal
screenings of newborns directly after delivery to identify
a possible introduction of VRE into the neonatal ICU
from other wards/outside (see below); (h) extended bar-
rier precautions also for family members of the neonatal
patients. Comprehensive epidemiological and infection
control analyzes in the described neonatal setting were
neither able to identify the source of the vanB type
strains nor reliable routes of transmission.
Recurrent introduction of VRE by patient admissions
into the neonatal ICU was evaluated as a possible risk
factor for a high VRE prevalence. Most neonatal patients
were directly admitted after delivery to the neonatal ICU
(median age of 0 months). An one-month screening
(rectal swabs) of 100 neonates directly after delivery and
before attending the neonatal ICU did not reveal any
positive VRE result (but 56 with bacterial growth in gen-
eral) excluding mothers and other family members as
potential sources (not described in details).
After introducing extended barrier precautions also for
family members of the neonates in August 2009, VRE
cases dropped continuously (09-12/2008: n = 58; 2009:
n = 71; 01-09/2010: n = 13) and from 2011 on, new VRE
cases were not noticed.
Clinical case descriptions
A retrospective analysis of clinical data of all identified
neonatal VRE cases between 2008 and 2010 (n = 158)
revealed valid and retrospectively analyzable data for
about two third of them (n = 103). Vast majority of VRE
cases were colonizations (anal/rectal, skin, throat); three
babies were diagnosed with an enterococcal infection:
one with a catheter sepsis, one with a necrotising enter-
ococolitis and one with high enterococcal yields clinic-
ally linked to a ventilator-associated pneumonia (role of
Enterococcus questionable); nevertheless, ten neonatal
patients received linezolid therapy due to a suspected
VRE infection.
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For all 71 vanB VRE isolates available for a further ana-
lysis the MICs were determined. All E. faecium isolates
were resistant to ampicillin and susceptible to teicopla-
nin, chloramphenicol, linezolid and daptomycin. Resis-
tances to other antimicrobials appeared as follows:
erythromycin in 67 (94%), ciprofloxacin (high-level) in
64 (90%), gentamicin (high-level) in 59 (83%), strepto-
mycin (high-level) in 23 (32%; but 40 [56%] had an MIC
of 512 mg/L), vancomycin in 33 (46%), tetracycline in 7
(10%) and quinupristin/dalfopristin 3 (4%) and tigecy-
cline 1 (1%; MIC of 1 mg/L).
PCR results
For all isolates initial PCR results were confirmed; all

































































Figure 1 Distribution of vancomycin MICs. (a) Vancomycin MICs of the
strains (dark grey) determined by microdilution in cation-adjusted Mueller-
outbreak VRE tested on MH agar using McFarland standard 0.5 and (c) and
vancomycin MIC from microdilution in cation-adjusted Mueller-Hinton brot
dotted line in Figure 1a depicts the EUCAST breakpoint for clinical resistanc
breakpoint of ≥32 mg/L (CLSI intermediate range of 8–16 mg/L, susceptibl
the bars display the number of isolates. Please notify that EtestW Vancomyc
concentrations than doubling dilutions assessed in MH broth microdilutionleading to four which were negative for both genes.
The vancomycin MIC distribution of the 67 VanB
strains only is shown in Figure 1a revealing 34 strains
(51%) with an MIC in the susceptible range of
≤4 mg/L according to CLSI and EUCAST criteria (see
also below). All isolates showed a signal for IS16 and
almost all were positive for esp (n = 76; 97%) and
hylEfm (n = 70; 90%).
SmaI macrorestriction in PFGE
To resolve a possible outbreak scenario we subjected
all E. faecium isolates to SmaI macrorestriction ana-
lysis in PFGE. Altogether 56 isolates constituted a
single cluster which was already obvious by visual in-
spection after clustering (optimization 0.5, tolerance


































67 vanB type VRE (light grey) and of the subset of 56 vanB outbreak
Hinton broth. (b) EtestW Vancomycin results of the 56 vanB type
on Brain Heart Infusion agar using McFarland standard 2.0. The
h was included in Figures 1b and 1c for reasons of comparison. The
e of >4 mg/L and the dashed line depicts the CLSI resistance
e breakpoint for EUCAST and CLSI is ≤4 mg/L). The numbers on top of
in allows assessing a broader spectrum of antibiotic dilution
.
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as “outbreak strain type” or “outbreak isolates”. Iso-
lates constituting the main cluster type derived from
52 neonatal patients; two isolates were from environ-
mental sources and three originated from the same
patient. The 15 non-outbreak strains revealed several
smaller clusters or individual patterns, among them a
pair of isolates with one isolate being vanA/B-nega-
tive (UW7620) and another one being vanB-positive
(UW7610), the former being obviously the susceptible
progenitor of the latter isolate having acquired a vanB
gene cluster. We were unable to identify a vanB-
negative progenitor isolate of the VanB type outbreak








































































Figure 2 Clonal relatedness of all investigated 71 enterococcal isolate
subsequent phylogenetic analysis (Dice co-efficient using UPGMA clu
1.0%). An 80% similarity line (dashed line) divides the group of the 56 rela
line) from the other 15 “non-outbreak” strains (below the dotted line). Lege
cation-adjusted Mueller-Hinton broth; Etest VAN is the value after 24 h read
NEW represents a previously unrecognised MLST type with the pattern [9-1MLST analysis
Altogether ten strains representing the outbreak strain
type were MLST typed. They were from different
branches of the PFGE tree and all revealed the same se-
quence type ST192 (Figure 2). The two van-negative and
vanB-positive isolates with the same PFGE pattern were
ST117. Isolates representing individual PFGE patterns
revealed ST203 (2 isolates) and ST192 (“non-outbreak”
ST192 type). Results of molecular screening tests were
congruent with the typing results. All isolates belonging
to the outbreak strain (PFGE) type were esp- and hylEfm-
positive. Prevalence of both markers varied among the
other 15 non-outbreak strains confirming the diverse
strain background of these isolates.esp hylEfm genotype MIC VAN Etest VAN Patient no. Source
elpmasloots3262Bnav++
+ + vanB 2 12 39 anal swab
eniru04218Bnav++
+ + vanB 4 12 8 unknown
elpmasloots03618Bnav++
bawslana13218Bnav++















+ + vanB 8 16 32 stool sample
elpmasloots33214Bnav++
gulpGCE,rotabucnI-618Bnav++































+ + vanB 32 48 4 stool sample
+ - vanB 16 n.d. 7 unknown
+ - - ≤1 n.d. 13 unknown




+ - vanB 128 n.d. 51 unknown
--- ≤1 n.d. 60 stool sample
-+- ≤1 n.d. 61 anal swab 
+ - - ≤1 n.d. 62 skin swab




+ + vanB 8 n.d. - Monitor
s as based on SmaI macrorestriction analysis in PFGE and
stering; BioNumerics v 6.5; settings: optimization 0.5%; tolerance
ted ST192 vanB-type outbreak isolates (above the horizontal dotted
nd: MIC VAN represents the MICs determined in microdilution in
out on MH agar and using McFarland 0.5; n.d., not determined; ST-
-1-1-12-7-1] which is a single locus variant of ST80.
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Altogether 31 (55%) isolates of the outbreak vanB
strain type had an MIC in the susceptible range of
≤4 mg/L (Figure 1) similar to results of the primary
analysis using vancomycin disk diffusion. All 56 iso-
lates were PCR-positive for genes esp, hylEfm and IS16
(and vanB). In general, vancomycin EtestW MICs on
MH agar were 1–2 doubling dilutions higher than in
MH broth (Figure 1b,c). EtestW Vancomycin MICs on
MH and BHI agar revealed two VRE (24/48 h) with a
susceptible result of ≤4 mg/L only (Figure 1b,c). The
48 h EtestW Vancomycin MIC of VanB strains was com-
monly 0.5 - 1 doubling dilutions higher than after the 24 h
readout, whereas it remained constant for susceptible
reference isolates (Figure 1b,c). Performance of three
chromogenic VRE agars to identify the 56 vanB type out-
break VRE was evaluated. On BrillianceTM VRE agar, three
isolates did not grow and two showed growths of small
colonies only. The chromIDTM VRE agar showed a similar
performance with three isolates that did not grow and one
isolate that showed growth of small colonies only. On
CHROMagarTM VRE two isolates did not grow and an-
other two grew with small colonies.Determination of the vanB subtype
The long PCR products amplified with DNA from nine
ST192 outbreak isolates and three non-outbreak isolates
(ST117; “non-outbreak ST192”; ST203) were subse-
quently digested with BspH1/Dra1. All but one showed
a unique restriction pattern which is type-specific for
vanB2 subtype clusters (Additional file 1: Figure S1). AM 1 2 3 4 5 6 7 8 9 10 11 12 13 M  
(a)
Figure 3 Chromosomal localization of vanB2 in E. faecium outbreak a
resolved in PFGE; (b) Southern hybridisation with a labelled vanB probe. Un
ST192 outbreak strain; NO, non-outbreak strains. M, S. aureus x SmaI; 1, UW
UW7842(O); 7, UW7610 (NO, ST117); 8, UW7611 (O, ST192); 9, UW7835 (O);
UW7852 (NO, ST203); 13, UW7859 (NO, ST-NEW).single non-outbreak strain (ST203) possessed an identi-
cal pattern but an additional band.Localisation of vanB
We performed different analyses with a set of nine
MLST typed outbreak and four non-outbreak strains. To
resolve the plasmid vs. a chromosomal localization we
isolated the plasmids from 13 strains (see above; plus
one additional ST203 isolate). The plasmid profiles of
the nine outbreak strains were similar, the patterns of
the four non-related strains differed; however, Southern
hybridisations with a labelled vanB probe did not reveal
any signal (Additional file 2: Figure S2). Nevertheless, we
performed PCRs for the three most common E. faecium
plasmid types determined by their replicase genes, which
were positive for rep(pRUM)(rep17 family according to
[15]), rep(pRE25(rep2 family)), and rep(pLG1)(repA_N
family, new class according to [16]) in all outbreak
ST192 isolates and different for the other four isolates
representing various sequence types (not shown in
details). A single Ceu-I band of ca. 260 kb hybridised to
the vanB gene probe in all PFGE lanes confirming the
chromosomal localization of this determinant (Figure 3).Conjugation experiments
Altogether nine outbreak ST192 isolates (UW7606,
UW7609, UW7611, UW7612, UW7813, UW7819,
UW7835, UW7842, UW7845) were used as donors for
in vitro filter-mating experiments and E. faecium 64/3 as a
recipient. Only one mating experiment revealed transcon-
jugants (UW7606) with a very low mating rate of 1,67 xM 1 2 3 4 5 6 7 8 9 10 11 12 13 M 
(b)
nd non-outbreak strains. (a) Genomic DNA digested with I-CeuI and
derlined lane numbers designate “non-outbreak strains”. Legend: O,
7606(O); 2, UW7609(O); 3, UW7612(O); 4, UW7813(O); 5, UW7819(O); 6,
10, UW7837 (NO, ST192); 11, UW7845(O); 11, UW7852 (NO, ST203); 12,
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spectively. A single transconjugant TC1 was investigated
in details. TC1 became resistant to vancomycin but
remained susceptible to erythromycin, gentamicin, ampi-
cillin and ciprofloxacin. It was PCR-positive for IS16 (re-
cipient 64/3 is IS16-negative) most probably due to
acquisition of a mobile vanB gene cluster which is com-
monly flanked by copies of IS16 [5]. PFGE analysis of the
donor, the recipient and the transconjugant followed by
subsequent Southern hybridisation with a labelled vanB
gene probe confirmed the clonal relatedness of the recipi-
ent and the transconjugant, the latter having acquired a
mobile vanB gene cluster from the donor which integrated
into the chromosome (Additional file 3: Figure S3).
Discussion
It has not been investigated in greater details until now to
which extent VanB type strains may show a low expres-
sion of vancomycin resistance which could result in a dis-
tinct frequency of underestimation or underreporting of
vanB type resistance in Enterococcus spp. in general.
Results of our present study (Figure 1) and annual reports
from our Focal laboratory for enterococci already demon-
strated that low resistance expression among vanB type
strains was prevalent in 10–25%, dependent on the
method and breakpoints used [10,20]. It has to be noted
again that in the present setting samples were screened
non-selectively and selected enterococcal colonies were
later tested for glycopeptide resistance phenotypically and
genotypically. Most strategies to identify vanA- or vanB-
type VRE start with selective enrichment or direct selec-
tion on screening plates which would certainly miss a sub-
stantial amount of strains showing low vancomycin
resistance expression (see below). This general strategy
may already pre-select the detectable wildtype vanB popu-
lation. Nevertheless, non-selective screening was success-
ful in this setting with premature infants lacking an
established intestinal flora. In adult patients VRE account
only for a certain percentage of all intestinal enterococci
and non-selective screening would most likely be unable
to select (by chance) for resistant variants [21]. Also real-
time based screening assays targeting only the resistance
genes vanA and vanB are not considered as a reliable al-
ternative for screening since prevalence of vanB genes in
non-enterococcal, intestinal colonizers complicates assay
accuracy and leads to false positive test results [22-25].
The numbers are comparably similar in different parts of
the world resulting in a generally low positive predictive
value for VanB and the demand for a confirmation by cul-
ture based methods (with the problems as described
above)[22,26,27]. In the light of our present study results,
it cannot be excluded that the generally high false-positive
vanB rate of real-time based genotypic assays could also
result from the low performance of comparator assays toidentify VanB strains with low vancomycin resistance
levels and may thus to a lesser extent be attributed to
vanB prevalent in non-enterocococcal species.
We assessed the performance of three commercially
available chromogenic VRE selective agar plates in iden-
tifying the 56 VanB type outbreak E. faecium isolates
with partly low level vancomycin resistance expression
and compared it to results of EtestW Vancomycin MICs
based on two different protocols. In general, MICs were
1–1.5 doubling dilutions higher on solid media (EtestW)
than in liquid broth (Figure 1). In line with these results
the three chromogenic agar media also performed com-
parably well in identifying vanB type VRE. A supposed
better vancomycin resistance expression of vanB on
solid media is an important finding, but observed here
on a collection of admittedly similar isolates and thus
cannot be extrapolated to the vanB VRE population in
general.
At least two of the 56 outbreak VRE isolates originated
from the patients’ surrounding and were clonally identi-
cal to the other patients’ isolates (Figure 2). Together
with all the described infection control measures one
might conclude that despite all rigid disinfection, infec-
tion prevention and training procedures, environmental
VRE contamination remains a possible source for this
ongoing VRE prevalence over three years. It is known
for a long time that VRE carriers contaminate their dir-
ect surrounding and that VRE/enterococci are able to
survive for weeks and months on these surfaces and
patients commodities [28,29] and are thus able to spread
to and colonise other patients. A common strategy to
decolonise VRE patients and newborns is not estab-
lished; however, results of recent experimental studies
pinpoint towards strategies by eliminating VRE colonisa-
tion with probiotic competitor strains [30].
A number of European countries reported increasing
numbers of colonisations and infections with VanB type
VRE. Sweden having had extremely low overall VRE
prevalence over the years experienced several clusters of
colonisations and infections in hospitals in Stockholm
recently [3,31]. Molecular analysis revealed distribution
of vanB2-Tn5382 subtype clusters located on pRUM-
like transferable plasmids introduced into hospital-
associated E. faecium strain types [7,8]. A similar resist-
ance gene cluster was shown to be prevalent among
various E. faecalis and E. faecium strains in 16 hospitals
in Chile [32] although in general vanA-type resistance
seemed most prevalent among Latin American VRE iso-
lates (Peru, Colombia, Ecuador, Venzuela)[33]. A num-
ber of reports described vanB type VRE outbreaks in
recent years among hospital patients in Spain and
France representing European low VRE prevalence
countries according to EARS-Net data [4,34-36].
Whereas the outbreaks in Spain remained at a local level
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overall surveillance numbers; increasing VRE frequencies
in France in 2008 are mainly attributed to a marked in-
crease in a number of vanB outbreaks in the North of
the country [4]. Similar rates are notified for Germany
after 2008, at least for some federal states mainly in the
South-Western part of the country [10].
During the ongoing outbreak also other non-outbreak
vanB isolates were identified. It remains to be speculated
if the identified vanB2-Tn5382 cluster as part of an ICE
is capable of spreading horizontally from strain to strain
and integrate into a recipients’ genome. Molecular ana-
lysis revealed a similar cluster type and a chromosomal
localization in all VanB strains. Resistance spread at a
very low mating rate as assessed in vitro. Nevertheless, it
was shown recently that vancomycin resistance genes
are transferred successfully in vivo in mammal intestines
and that rates could be several orders of magnitude
higher than those determined in vitro [37-39].
Various expression levels of vancomycin resistance in
vanB strains were known for some time. The level of
vanB gene expression and the presence of a distinct
vanB allele type (vanB1 to vanB3) could not be genetic-
ally linked. Grabsch et al. were unable in identifying mu-
tational changes in unrelated vanB2 type VRE showing a
various level of vanB gene expression [40]. Teicoplanin
heteroresistance in vanA VRE strains was described re-
cently and several genomic rearrangements and dele-
tions within the vanA gene cluster elements and
mutational changes within the two-component regulator
genes vanS and vanR were identified in glycopeptide-
heteroresistant strains, but these changes were not (ex-
perimentally proven) functionally linked to the described
heteroresistance phenotype [41-43]. We did not investi-
gate the molecular background of different vanB resist-
ance expression in the isolates investigated here.
Nevertheless, MICs were reproducible in repeated
experiments.
Conclusions
We analysed an ongoing high prevalence of vanB type E.
faecium in a neonatal ICU over a period of several years;
ca. 80% (n= 56) of isolates collected during a key period of
10 months belonged to a single outbreak strain type.
Enterococcal isolates were assessed non-selectively and
about half of the isolates appeared phenotypically suscep-
tible to vancomycin with MICs ≤4 mg/L. This suggests
that a certain amount of VanB strains may show a low ex-
pression of vancomycin resistance which results in an un-
known frequency of underestimation or underreporting of
vanB type resistance in Enterococcus spp in general. It is
tempting to speculate that this phenomenon may directly
support ongoing and increasing prevalence of
(unrecognized) vanB VRE prevalence among the clinicalsetting. The comparably high false-positive vanB rate of
real-time based genotypic assays may thus only be partly
attributed to vanB prevalent in non-enterocococcal spe-
cies but could also simply result from the low accuracy of
comparator assays to identify VanB strains with low ex-
pression of vancomycin resistance.
Additional files
Additional file 1: Figure S1. vanB2 subtype determination. Long PCR
products with DNA from outbreak and non-outbreak strains were
subsequently digested with BspH1/DraI. Underlined lane numbers
designate “non-outbreak strains”. Legend: O, ST192 outbreak strain; NO,
non-outbreak strains. M, Gene Ruler 100bp Plus (Thermo Fisher Scientific);
1, UW7606(O); 2, UW7609(O); 3, UW7612(O); 4, UW7813(O); 5, UW7819(O);
6, UW7842(O); 7, UW7610 (NO, ST117); 8, UW7611 (O, ST192); 9, UW7835
(O); 10, UW7842 (O); 11, UW7845(O); 12, UW7852 (NO, ST203) [UW7859
(NO, ST203) did not reveal a long PCR product; not shown].
Additional file 2: Figure S2. Plasmid patterns of vanB2 E. faecium
outbreak and non-outbreak strains. (a) Undigested plasmid patterns
resolved in 0.8% agarose gel; (b) Southern hybridisation with a labelled
vanB probe. Underlined lane numbers designate “non-outbreak strains”.
Legend: O, ST192 outbreak strain; NO, non-outbreak strains; M, Roche Size
Marker III, DIG-labelled (for orientation purposes only); 1, UW7606(O); 2,
UW7609(O); 3, UW7612(O); 4, UW7813(O); 5, UW7819(O); 6, UW7842(O); 7,
UW7610 (NO, ST117); 8, UW7611(O, ST192); 9, UW7835 (O); 10, UW7845
(O); 11, UW7852 (NO, ST203); 12, UW7859 (NO, ST203).
Additional file 3: Figure S3. (a) SmaI-digested genomic DNA resolved
in PFGE and (b) Southern hybridisation with a labelled vanB probe of a
vanB type E. faecium donor strain UW7706, a vancomycin-susceptible
recipient E. faecium 64/3 and a vanB-positive transconjugant 1. Legend:
M, S.aureus x SmaI. D, donor strain UW7706; R, recipent strain 64/3; T,
transconjugant UW7706x64/3 TC1. Please note that the vanB positive
band in lanes D and T refers to a double band.
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